April 2024 Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS

April 29, 2024

Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS

Dear CredibleMeds Registrants:

AZCERT's Scientific Review Committee for the QTdrugs List has found substantial evidence that the following medications are associated with the development of QT prolongation but lack convincing evidence of torsades de pointes (TdP):

• Moclobemide (antidepressant)
• Gepirone (antidepressant)
• Motixafortide (Multiple myeloma therapy)
• Givinostat (Duchenne muscular dystrophy therapy)
• Isoflurane (general anesthetic)

Therefore, these medications have been added to the Possible Risk of TdP category (PR) and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List). 

Also, the Committee found substantial evidence that Ivabradine (antianginal drug), previously in the Conditional Risk of TdP category, is associated with QT prolongation and TdP when used as directed.  Therefore, Ivabradine has been changed to the Known Risk of TdP category.  In addition, Quizartinib (leukemia therapy) was added to the Known Risk of TdP category on February 5, 2024.

As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly.  To perform a quick search of the Lists we recommend using the CredibleMeds website and the smartphone app (Apple or Android).  Please note that the CredibleMeds Android app is temporarily unavailable but will soon be back in the Google Play App Store.

Best wishes,

Ray Woosley and the Scientific Review Committee for AZCERT
Will Heise, MD, Tyler Gallo, PharmD, R. David Woosley, MPH, Joseph Lambson, PharmD